Department of Neurology, Baylor College of Medicine, Houston, Texas, USA.
Department of Neuro-oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
World Neurosurg. 2019 Aug;128:127-130. doi: 10.1016/j.wneu.2019.04.266. Epub 2019 May 9.
Papillary glioneuronal tumors (PGNTs) are rare World Health Organization grade I neoplasms that are characterized by a benign course and excellent response to surgical resection. A few reports exist of tumors with more aggressive clinical and histologic features. In this report we detail the case of an unusually aggressive PGNT in a 67-year-old woman.
The patient had a 3-year history of seizures and was diagnosed with a frontoparietal mass on imaging. She underwent subtotal resection with a histologic diagnosis of PGNT. Less than a year after surgery, the patient experienced recurrence of disease and underwent reresection and adjuvant radiation treatment. The patient's disease continued to progress despite radiation treatment, so adjuvant temozolomide was initiated. Molecular testing was performed and revealed a TERT promotor mutation, an FGFR3-TACC3 oncogenic fusion, and a copy number loss in CDKN2A/CDKN2B.
PGNTs, while typically benign, can rarely recur after surgery. Molecular testing should be performed on all PGNTs to help possibly identify more aggressive tumors and potentially reveal novel treatment options.
乳头状胶质神经元肿瘤(PGNTs)是罕见的世界卫生组织(WHO)I 级肿瘤,其特点是良性病程和对手术切除的良好反应。少数具有侵袭性临床和组织学特征的肿瘤已有报道。本报告详细介绍了一例 67 岁女性具有侵袭性行为的 PGNT。
患者有 3 年癫痫病史,影像学检查诊断为额顶叶肿块。她接受了次全切除术,组织学诊断为 PGNT。术后不到一年,患者疾病复发,再次接受了肿瘤切除术和辅助放疗。尽管进行了放疗,患者的疾病仍在进展,因此开始使用替莫唑胺辅助治疗。进行了分子检测,结果显示存在 TERT 启动子突变、FGFR3-TACC3 致癌融合以及 CDKN2A/CDKN2B 的拷贝数缺失。
PGNTs 虽然通常为良性,但手术后也可能罕见复发。所有 PGNTs 都应进行分子检测,以帮助可能识别更具侵袭性的肿瘤,并可能揭示新的治疗选择。